Swing Trade Ideas

🏃🚀✅ NBY2.52, 23% 🚀

🏃🚀✅ TLRY 1.88,  65% 🚀

 🏃🚀✅ ACRV 1.83 ,18% 🚀

🏃🚀✅ CTMX 3.65, up 55% 🚀

🏃🚀✅ PEPG 6.40, up 392% 🚀

🏃🚀✅ OFAL 2.47, up 60% 🚀

🏃🚀✅ ZONE 4.29, up 115% 🚀

🏃🚀✅ SLNH  550% high  3.58  🚀

🏃🚀✅ SILO  1.340, up 106% 🚀

🏃🚀✅ SNGX  3.49, up 27% 🚀

🏃🚀✅ BITF  3.50, up 170% 🚀

🏃🚀✅ SONN  7.98, up 141% 🚀

🏃🚀✅ MXCT 1.55, up 15% 🚀

🏃🚀✅ SLNH  1.48, up 169% 🚀

🏃🚀✅ OPEN  10.98, up  448% (from Aug swing) 🚀

🏃🚀✅ TGL  2.04, up  94% (from mid July swing) 🚀

🏃🚀✅ ZONE 9.0, up 200% 🚀

🏃🚀✅ MXCT 1.42, up 5% 🚀

🏃🚀✅ HWH (from August recent swing, high 7.43, up 470% 🚀

🏃🚀✅ EDBL 2.62, up 45% 🚀

  ✅ TMDE potential entry: $0.75 – $0.80
🎯 Potential PT1: $1.20 – $1.40, 🎯 PT2: $1.50 – $1.80, 🎯 PT3: $1.90 – $2.40
🚫 Potential Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-driven | Technical setup
Back to support from recent high above 4.35, small float, recently announced partnership with Double Corporate for Green Bioenergy Expansion, previously announced expansion into oil waste collection, company specializes in the supply and marketing of marine gas oil and marine fuel oil based in Malaysia and Singapore,, also offers ship management services and vessels chartering. recent IPO 

 ✅ GNS potential entry: $0.90 – $0.95
🎯 Potential PT1: $1.20 – $1.60, 🎯 PT2: $1.70 – $2.20, 🎯 PT3: $2.30 – $2.80
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-driven | Technical setup 

 Back to support from recent high,  recently signed $14M share purchase, joint venture agreement,  company focuses on education, provides training, business tools, AI curriculum, acceleration across regions, recent form 4 discloses CEO Roger Hamilton recent purchased 650,000 average price ~.54/share,  recent purchased in September 500,000 average price ~0.94/share, other board directors/executives purchased 100,110 shares average .93/share, 

 ✅ INEO potential entry: $1.00 – $1.05
🎯 Potential PT1: $1.30 – $1.70, 🎯 PT2: $1.80 – $2.30, 🎯 PT3: $2.40 – $2.80
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Company focuses on oncology, use a proprietary proteomics/phosphoproteomics platform (AP3) to match tumor's signaling pathways to drug mechanisms, Citizens JMP buy rating, Oppenheimer price target $8, Piper Sandler buy rating 

 ✅ TDTH potential entry: $0.80 – $0.90
🎯 Potential PT1: $1.20 – $1.60, 🎯 PT2: $1.70 – $2.20, 🎯 PT3: $2.30 – $2.70
🚫 Potential Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Recently competed $2.6M PIPE financing, also recently acquired 30% stake in Web 3.0 E-commerce platform, planning to pursue regulatory approvals for stablecoin operations across several African countries, company focuses on digital transformation, IT consulting, e-commerce enablement, and Web 3.0 identity/digital identity solutions 

 ✅ $ACRV potential entry: $1.55–$1.60
🎯 Potential PT1: $1.80–$2.30, 🎯 PT2: $2.40–$2.80, 🎯 PT3: $2.90–$3.40
🚫 Potential Stop: Below $1.30 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Company focuses on oncology, use a proprietary proteomics/phosphoproteomics platform (AP3) to match tumor's signaling pathways to drug mechanisms, Citizens JMP buy rating, Oppenheimer price target $8, Piper Sandler buy rating 

 ✅ $PRSO potential entry: $1.05–$1.15
🎯 Potential PT1: $1.40–$1.80, 🎯 PT2: $1.90–$2.40, 🎯 PT3: $2.50–$2.70
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Recently regained compliance, previously secured $1.1M through inducement offer agreement, ,secured $0.9M order from FWA equipment supplier, partnered with WeLink to expand access to high-speed broadband across dense US metro areas, company focuses on fabless semiconductor/mmWave wireless technology, , Benchmark Co buy rating, price target $3 

 ✅ CMND potential entry: $1.00 – $1.05
🎯 Potential PT1: $1.30 – $1.70, 🎯 PT2: $1.80 – $2.40, 🎯 PT3: $2.50 – $2.70
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Near 52wk low, recently published international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD), does have mixed shelf, be mindful on next spike 

 ✅ SMX potential entry: $1.35 – $1.45
🎯 Potential PT1: $1.70 – $1.90, 🎯 PT2: $2.05 – $2.50, 🎯 PT3: $2.60 – $2.80
🚫 Potential Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Back to near support from recent high, recently announced collaboration with $BBAI to enhance maritime awareness for U.S Navy, also recently announced breakthrough in plastic recycle with Successful trials, company focuses on authentication, brand protection, and track-trace/anti counter solutions using molecular hardware level verification and marking 

✅ SABS potential entry: $2.05 – $2.10
🎯 Potential PT1: $2.40 – $2.80, 🎯 PT2: $2.90 – $3.40, 🎯 PT3: $3.50 – $3.80
🚫 Potential Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Back to support from recent high near 3, company focuses on immunotherapies, lead platform, DiversitAb, involves producing fully human polyclonal antibodies using genetically engineered cattle that generate human antibodies in response to antigens, goal is to treat unmet medical needs in areas such as infectious disease, immune disorders,  Chardan Capital price target $14, Leerink Partners price target $7, Craig-Hallum buy rating, HC Wainwright price target $9, Zacks price target $9,  does have active mixed shelf, be mindful on next spike 

 ✅ CTMX potential entry: $2.30 – $2.35
🎯 Potential PT1: $2.50 – $2.90, 🎯 PT2: $3.00 – $3.60, 🎯 PT3: $3.60 – $4.10
🚫 Potential Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Company focuses on developing Probody therapeutics, a proprietary platform activated antibody-based treatments engineered to remain inactive in circulation and healthy tissues, but active within the tumor microenvironment, UPCOMING CATALYST: Initial data for phase 1, biomarker data, CX-801, interferon alpha-2b PROBODY cytokine, localizing immune activation with tumors while reducing systemic toxicity in metastatic melanoma, combination with Keytruda,  2nd half 2025, CX-2025 phase 1 colorectal cancer update Q1 2026, company in active collaboration with partners including $AMGN $REGN $MRNA  $ALPMF $BMY, Piper Sandler price target $5,  HC Wainwright upgraded to buy price target $5, Barclays buy rating, Cantor Fitzgerald price target $6, Oppenheimer Buy rating, does have mixed shelf, be mindful on next spike

✅ BTBT potential entry: $2.95 - $3.05
✅ $ACRS potential entry: $1.75 – $1.85
🎯 Potential PT1: $2.20 – $2.50, 🎯 PT2: $2.60 – $2.90, 🎯 PT3: $3.00 – $3.40
🚫 Potential Stop: Below $1.60 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Another rinse and repeat from recent high above 2, potential swing 1.80/.85, stop if below 1.60 or daily max risk per trade, upcoming catalysts: 1) phase 1b data  end of 2025 for investigational bispecific anti-TSLP/IL-4R antibody ATI-052, 2) top line early 2026, followed by top line results from phase 1b portion 2nd half 2026,  3) results for phase 2 trial Anti-TSLP monoclonal antibody Bosakitug in patients with mod to severe AD 2nd half of 2026, Wedbush buy rating price target $8, HC Wainwright buy rating price target $16, Scotiabank price target $9, Piper Sandler buy rating  

 ✅ $NBY potential entry: $2.00 – $2.05
🎯 Potential PT1: $2.25 – $2.70, 🎯 PT2: $2.80 – $3.40, 🎯 PT3: $3.50 – $3.70
🚫 Potential Stop: Below $1.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Back to support from recent high above 4 on special dividend declaration, company is a specialty pharma company, main focus is non-antibiotic anti-infective products, recent 13D filing shows David Lazar 19.99% stake in the company as of 8/19/2025, Zacks upgraded to buy rating, 

✅ BTBT potential entry: $2.95 - $3.05
🎯 PT1: $3.30 - $3.65, 🎯 PT2: $3.80 - $4.30, 🎯 PT3: $4.50 - $5.00
🚫 Stop: Below $3.00 or 2%-5% or daily max risk per trade 

🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Another rinse and repeat, recent offering price $3.06 share, recently announced has purchased approximately 19,683 $ETH.X , holding a total of  120,306, previously announced it rebranded its high-performance computing business as WhiteFiber, which recently filed for IPO under symbol $WYFI, Noble Financial buy rating, HC Wainwright Buy rating price target $7, Craig-Hallum buy rating, Northland Securities buy rating, CEO  Samir Tabar and Director Brock Pierce recently purchased shares (~750,000 and 500,000, respectively) ~ $2/share 

 ✅ ZONE potential entry: $1.90 – $1.80
🎯 Potential PT1: $2.40 – $2.80, 🎯 PT2: $3.0 – $3.50, 🎯 PT3: $3.60 – $4.40
🚫 Potential Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

 Another rinse and repeat. back to support from recent high above $9,  recently acquired additional 10 million DOGE.X, also recently announced chief investment officer and partnered with $HOOD digital division, previously secured multi-million dollar contract for logistics firm, also recently entered sales agreement with Curvature, completed acquisition of Sanzonate Europe, enhancing leadership position within the industry, awarded $475,000 GSA contract, launched product rollout at New York airport, company makes devices that infuse water with ozone (pure aqueous ozone) for chemical-free cleaning in commercial/industrial settings (airports, hotels, education) 

 ✅ PDSB potential entry: $1.05 – $1.10
🎯 Potential PT1: $1.40 – $1.70, 🎯 PT2: $1.80 – $2.40, 🎯 PT3: $2.50 – $2.80
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Back to support from recent high, company develops precision cancer immunotherapies using its proprietary Versamune lipid nanoparticle platform, which stimulates strong T-cell activation to target disease antigens, current pipeline: Versamune HPV  Combines with pembrolizumab (Keytruda) to treat HPV16-positive cancers like head & neck, cervical, anal, vagina, and vulvar cancers, and PDS01ADC to treat colorectal cancer, HC Wainwright price target $13, DOES have mixed shelf, be mindful on next big spike 

 ✅ ICCM potential entry: $0.95 – $1.00
🎯 Potential PT1: $1.20 – $1.60, 🎯 PT2: $1.70 – $2.20, 🎯 PT3: $2.30 – $2.70
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

 Back to consolidation from recent high, recently  secured US patent for Next-Gen XSense Crypoprobes, also received approval in Israel for the XSense System, announced positive clinical data for ProSense Crpoablation in breast cancer, HC Wainwright price target $2, Brookline Capital buy rating,  company develops and markets cryoablation system (using liquid nitrogen) to destroy tumors, both benign and malignant by freezing, its main product, Prosense, is used (seeking regulatory approval) for tumor ablation in breast, kidney, lung, bone, does have mixed shelf, be mindful on next spike 

 ✅ RCKT potential entry: $3.03 – $3.08
🎯 Potential PT1: $3.40 – $3.70, 🎯 PT2: $3.80 – $4.30, 🎯 PT3: $4.50 – $5.30
🚫 Potential Stop: Below $2.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Back to support from recent high on, Director Elisabeth Bjork recently purchased $34.1k in common stock, recently announced FDA lifted the clinical hold on phase 2 Trial of RP-A501 for treatment of Danon Disease, Bank of America buy rating price target $10, Chardan Capital Buy rating price target $11, Cantor Fitzherald price target $8, company focuses on rare/orphan diseases, especially pediatric and genetic ones 

 ✅ ZONE potential entry: $2.50 – $2.50
🎯 Potential PT1: $2.80 – $3.70, 🎯 PT2: $3.80 – $4.50, 🎯 PT3: $4.60 – $5.40
🚫 Potential Stop: Below $2.30 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

 Another rinse and repeat. back to support from recent high above $9, recently acquired additional 100 million $DOGE.X, recently secured multi-million dollar contract for logistics firm, also recently entered sales agreement with Curvature, completed acquisition of Sanzonate Europe, enhancing leadership position within the industry, awarded $475,000 GSA contract, launched product rollout at New York airport, company makes devices that infuse water with ozone (pure aqueous ozone) for chemical-free cleaning in commercial/industrial settings (airports, hotels, education) 

 ✅ BTAI potential entry: $3.05– $3.5
🎯 Potential PT1: $3.50 – $3.80, 🎯 PT2: $4.00 – $4.50, 🎯 PT3: $4.80 – $5.50
🚫 Potential Stop: Below $2.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Back to support from recent high above 7, recently announced positive results from phase 3 SERENITY At-home trial for agitation treatment in bipolar and schizophrenia patients, seeking FDA label expansion for schizophrenia treatment, recently announced completed enrollment in clinical study to evaluate mCGI-S and PEC Scale correlation, results expected Q4 2025, Mizuho price target $4, Canaccord Genuity buy rating, HC Wainwright price target $10, does have mixed shelf, be mindful on next spike, company focuses on AI to repurpose or expand existing drugs 

 ✅ SNGX potential entry: $2.70 – $2.75
🎯 Potential PT1: $3.00 – $3.60, 🎯 PT2: $3.70 – $4.30, 🎯 PT3: $4.40 – $5.10
🚫 Potential Stop: Below $2.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

 Back to support from recent high above 6.20, recently granted orphan drug designation to dusquetide, active ingredient for Behcet's disease, provides 7 years of U.S market exclusivity if approved, upcoming catalyst:  ongoing enrollment in phase 3 trial for HyBryte, company specializing in the development and commercialization of therapies for rare and underserved diseases,  Zacks Small-cap price target $35, Alliance Global Partners price target $6, 

 ✅ OTLK potential entry: $1.05 – $1.10
🎯 Potential PT1: $1.40 – $1.80, 🎯 PT2: $2.00 – $2.30, 🎯 PT3: $2.40 – $2.60
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High / fast-moving / technical setup 

Recently requested FDA meeting to clarify confirmatory evidence requirements for ONS-5010 Wet AMD Biologics license application, previously announced securing SMC approval for LYTENAVA as the first and only licensed ophthalmic Bevacizumab for Wet AMD (Wet Age-Related Macular Degeneration) treatment in UK, company focused on developing/commercializing therapies for retina/ophthalmic diseases 

✅ LGPS potential entry: $1.0 – $1.05
🎯 Potential PT1: $1.40 – $1.90, 🎯 PT2: $2.00 – $2.50, 🎯 PT3: $2.80 – $3.00
🚫 Potential Stop: Below $.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High / fast-moving / technical setup 

 Recently announced shares available for trading through Mitsubishi UFJ Morgan Stanley Securities, recently announced joint venture with Inmark Global, previously approved $543k share repurchased program to buy up to 1.087M shares through June 2026, company focuses in real-estate management & development 

 ✅ NRSN potential entry: $1.10 – $1.15
🎯 Potential PT1: $1.50 – $1.90, 🎯 PT2: $2.00 – $2.70, 🎯 PT3: $2.80 – $3.50
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Back to near 52wk low, recently announced positive trial results for Alzheimer's drug candidate, D. Boral Capital price target $14, its leading drug candidate, PrimeC, a combination of ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS) has shown positive clinical data in phase 2b, currently being prepared for commercial-scale production, upcoming catalyst: 1) topline data, phase 3, 2nd of half 2025, 2) full lNDS submission later of 2025, , company focuses on neurodegenerative diseases, primarily ALS, with additional pipeline programs targeting Alzheimer's and Parkinson's 

 ✅ KIDZ potential entry: $1.35 – $1.45
🎯 Potential PT1: $1.60 – $1.90, 🎯 PT2: $2.10 – $2.50, 🎯 PT3: $2.70 – $3.20
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat,  recently appointed former $MSFT researcher Xin Huang as AI development advisor to Drive AI education initiatives, previously announced $SOL.X holdings over $11M, also partnership announcement with Everstake to launch branded validator on Solana, previously announced $400M equity deal to back Solana-based treasury strategy, previously announced to hire 2500 US based teachers over next 12 to 24 months, company is an AI-powered education technology company based in New York, offering online live courses for k-12 students in US and internationally, does have mixed shelf, be mindful on next big spike 

 ✅ ADTX potential entry: $1.03 – $1.08
🎯 Potential PT1: $1.30 – $1.80, 🎯 PT2: $2.00 – $2.70, 🎯 PT3: $2.80 – $3.40
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Near 52wk low from recent high, recently partners with crypto.com for custodial crypto account and ADTX share access, its subsidiary Pearsanta, plans IPO with Spartan Capital to advance cancer detection technology, previously announced receive institutional IRB approval from WCG Clinical to initiate prospective clinical study evaluating Mitomic endometriosis, upcoming catalyst: 1) September 26,  expected merger approval for upcoming special meeting with $EVFM, early 2026 FDA submission for first-in-human trials in type 1 diabetes and stiff person syndrome, company focuses on developing and commercializing technologies aimed at improving immune system health through monitoring and modulation, does have active mixed shelf 

 ✅ ATER potential entry: $0.90 – $0.95
🎯 Potential PT1: $1.30 – $1.80, 🎯 PT2: $2.00 – $2.70, 🎯 PT3: $2.80 – $3.40
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Back to 52wk low from recent high,  small float, recently launched Squatty Potty wipes and PurSteam Steam Station Max and Mueller Living Cordless Portable Vaccuum Sealer at $WMT Nationwide, also launched multiple products on Bestbuy.com, , previously initiates $3m stock buyback plan,  company is a technology-driven consumer products specializing in e-commerce brands across various categories, portfolio includes : Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, Photo Paper Direct, which primarily sold through $AMZN $WMT $TGT and company's own direct-to-consumer websites. 

 ✅ SLNH potential entry: $0.50 – $0.60
🎯 Potential PT1: $0.80 – $1.20, 🎯 PT2: $1.30 – $1.70, 🎯 PT3: $1.80 – $2.50
🚫 Potential Stop: Below $0.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

Last offering price at $.55/share, recently surpassed 1-Gigawatt Milestone in clean data centers with new Texas Solar and wind projects, expanded partnership with Galaxy Digital with 48 MW $BIT.X Mining deployment at Texas Project, also recently expanded with new $20M funding and project Kati Construction launch, a wind-powered data center, with construction expected to begin Q3 2025,  company specializing in developing renewable-powered data centers for compute-intensive applications like $BIT.X mining and AL workloads, has until 11/4/2025 to regain compliance by bringing price above $1 for 10 consecutive trading days, does have option for second 180-day extension if needed. 

 ✅ TBH potential entry: $1.50– $1.60
🎯 Potential PT1: $1.70 – $2.20, 🎯 PT2: $2.30 – $2.80, 🎯 PT3: $3.00 – $3.50
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

 Recently announced $4M investment in CleanCore's $DOGE.X treasury model, recently launched secure digital assets platform for NIL initiative, recently featured on RedChip small stocks, big money show on Bloomberg TV, Zacks Small-cap research price target $4.40, company operates a Gen-Z focused esports and gaming platform 

 ✅ XTKG potential entry: $2.15 – $2.20  

🎯 Potential PT1: $2.50 – $2.90, 🎯 PT2: $3.00 – $3.60, 🎯 PT3: $3.70 – $4.50  

🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade  

🚦 Risk Level: 🔴 High / fast-moving / technical setup   

Back to near 52wk low from recent high,  Rcently acquired creation intelligent to boost gaming portfolio, company focuses on digital solutions and technology, operating across four primary segments: digital technologies, crypto mining, renewable energy, and Argi-tech, DOES have active mixed shelf, be mindful on next spike  upcoming catalyst: 1) data for phase 1 SENT-202 study in acute myeloid leukemia expected Q4, 

 ✅ BITF potential entry: $1.25 - $1.35
🎯 PT1: $1.50 - $1.80, 🎯 PT2: $2.00 - $2.50, 🎯 PT3: $2.60 - $3.20
🚫 Stop: Below $1.00 or 2%-5% or daily max risk per trade 

🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup  

Recently announced partnership with T5 Data Centers to boost AI Development in Pennsylvania, Clear Street price target $6, Northland Securities price target $3.25, HC Wainwright price target $3.50, Alliance Global Partners buy rating price target $3.25, company specializes in mining $BTC using its own infrastructure including data centers and energy assets 

✅ SNTI potential entry: $1.30 – $1.34  

🎯 Potential PT1: $1.50 – $1.85, 🎯 PT2: $2.00 – $2.60, 🎯 PT3: $2.70 – $3.30  

🚫 Potential Stop: Below $1.30 or 2%–5% or daily max risk per trade  

🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup
Back to near 52wk low from recent high, recently received FDA orphan drug designation for treatment of acute myeloid leukemia, recently received additional $1m from CIRM (California Institute for Regenerative Medicines) to support clinical development, Chardan Capital price target $12,  Laidlaw & Co price price $15, company focuses on the development of next-generation cell and gene therapies through tis proprietary Gene Circuit platform, lead candidate, SENT-202, upcoming catalyst: 1) data for phase 1 SENT-202 study in acute myeloid leukemia expected Q4, 

✅ ABVE potential entry: $1.60 – $1.65  

🎯 Potential PT1: $1.85 – $2.20, 🎯 PT2: $2.30 – $2.70, 🎯 PT3: $2.80 – $3.50  

🚫 Potential Stop: Below $1.50 or 2%–5% or daily max risk per trade  

🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup  

 Back to support from recent high above 4, recently secured $20m strategic investment from Aqua 1 Foundation, announced merger with Palm Global, company focused on sourcing regeneratively grown grains and processing them into sustainable food ingredients such as flours, proteins and starches across Canada, U.S Mexico, China France, Turkey 

 ✅ GFAI potential entry: $1.03 – $1.07
🎯 Potential PT1: $1.25 – $1.65, 🎯 PT2: $1.70 – $2.05, 🎯 PT3: $2.10 – $2.70
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup
Recently launched Smart Solutions in Thailand, also launched DVGO, an AI Travel planning tool powered by specialized AI agents in the United States, previously secured three-year renewal with Thailand's Government Saving Bank, D. Boral Capital price target 4.50, company is a global provider of integrated security solutions, specializing in both traditional security services and advanced AI and robotics technologies, offering services across regions throughout Asia 

 ✅ VTAK potential entry: $2.45 – $2.48
🎯 Potential PT1: $2.70 – $3.30, 🎯 PT2: $3.50 – $3.80, 🎯 PT3: $3.90 – $4.30
🚫 Potential Stop: Below $2.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven / technical setup 

  Back to near 52wk low, recent 1/19 reverse split, small float, recently received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery,  does have mixed shelf, 

 ✅ INAB potential entry: $2.05 – $2.15
🎯 Potential PT1: $2.50 – $2.80, 🎯 PT2: $3.00 – $3.40, 🎯 PT3: $3.60 – $3.90
🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven
Back to near 52wk low, has been in consolidation near support, recent 1/30 reverse split, small float, recently announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone—achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases, upcoming catalysts: 1) late summer and fall, continued interim data on phase 1/2 trials 

 ✅ LGVN potential entry: $0.70 – $0.75
🎯 Potential PT1: $0.95 – $1.30, 🎯 PT2: $1.40 – $1.85, 🎯 PT3: $2.00 – $2.40
🚫 Potential Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven

Recent drop due to offering price at 0.85 per share from high above 1.75, recently announced FDA approval of INDA application for laromestrocel study, FDA fast track & RMAT designations in Alzheimer's and pediatric indications, recently announced positive outcome of a type B meeting with FDA, supporting the advancement of laromestrocel, potential treatment for Alzheimer's disease, upcoming catalyst: 1) top-line trial expected Q3 2026, HC Wainwright price target $10 rating due to promising Alzheimer's treatment and favorable regulatory development, Zacks Small-Cap Research price target $9.55, Roth MKM buy rating , price target $3, 

 ✅ MAIA potential entry: $1.45 – $1.50
🎯 Potential PT1: $1.80 – $2.30, 🎯 PT2: $2.40 – $2.80, 🎯 PT3: $3.00 – $3.50
🚫 Potential Stop: Below $1.35 or 2%–5% or daily max risk per trade Near 52wk low, upper gap $2.0,  Near 52wk low from recent high, recently secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target $14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago, upcoming catalysts: 1) update clinical data on efficacy/safety for phase 2 

 ✅ CSAI potential entry: $1.30 – $1.35
🎯 Potential PT1: $1.55 – $1.90, 🎯 PT2: $2.00 – $2.60, 🎯 PT3: $2.70 – $3.30
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade 

 back to near 52wk low, small float, recently announced partnerships with National Property management firm to enhance security with AI Surveillance Solutions, also, announced partnership with Crypto-mining company to cut AI operation costs using renewable energy data center in Montana, won "Project Management Solution of the year", upcoming catalyst: present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025, company specializing in cloud-based video surveillance, storage, analytics and monitoring solutions, offering leverage AI and computer vision to enhance security systems, Analyst price target $6, buy rating,  does have active mixed shelf, be mindful on next spike 

 ✅ MXCT potential entry: $1.28 – $1.34

🎯 Potential PT1: $1.50 – $1.90, 🎯 PT2: $2.05 – $2.65, 🎯 PT3: $2.80 – $4.20

🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade 

Near 52wk low, upper gap $2.0, recently signed licensing deal with Adicet Bio to support development of gene-edited gamma delta T cell therapies,  recent partnership with Ori Biotech to enhance cell therapy manufacturing efficiency,  company sells ExPERT electroporation instruments, consumables and services that let biotech/CGT companies deliver DNA/RNA proteins into cells, Stephens & Co price target $6, Craig-Hallum buy rating, Stifel Nicolaus buy rating, Zacks Equity Research buy rating, BlackRock increases stake to 9.98% from 7.65% 6/5/2025,

✅ ZONE potential entry: $3.05 – $3.10
🎯 Potential PT1: $3.50 – $3.85, 🎯 PT2: $4.00 – $4.50, 🎯 PT3: $4.60 – $5.40
🚫 Potential Stop: Below $2.80 or 2%–5% or daily max risk per trade 

Dropped 61% after $175M private investment, expected to close on 9/4, recently secured multi-million dollar contract for logistics firm, also recently entered sales agreement with Curvature, completed acquisition of Sanzonate Europe, enhancing leadership position within the industry, awarded $475,000 GSA contract, launched product rollout at New York airport, company makes devices that infuse water with ozone (pure aqueous ozone) for chemical-free cleaning in commercial/industrial settings (airports, hotels, education)